Review Article
Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb
Table 9
Clinical trials performed with Novasorb.
| Year | Phase type | Product | Objectives | Indication | No. of patients |
| 2003 | Phase I | Vehicle no.1 | Tolerance and safety | None | 16 | 2004 | Phase II | Tolerance and safety, Exploratory efficacy | Dry eye | 50 | 2005 | Phase II | Cationorm (Vehicle no.2) | Efficacy, tolerance, and safety | Dry eye | 79 | 2010 | Phase II | Efficacy, tolerance, and safety | Dry eye | 71 | 2005 | Phase IIa | Cyclokat | Tolerance and safety Exploratory efficacy | Dry eye disease | 48 | 2008 | Phase IIb | Exploratory efficacy, tolerance, and safety | Dry eye disease | 132 | 2009 | Phase III “Siccanove” | Efficacy, tolerance, and safety | Dry eye disease | 496 | 2011 | Phase III “Sansika” | Efficacy, tolerance, and safety | Dry eye disease | 252 | 2006 | Phase IIb/III | Vekacia | Efficacy, tolerance, and safety | Active VKC | 118 | 2009 | Phase IIb | Efficacy, tolerance, and safety | Nonactive VKC | 34 | 2011 | Phase II | Catioprost | Exploratory efficacy, open-label study | Glaucoma | NA | 2011 | Phase IIb | Exploratory efficacy, tolerance, and safety | Glaucoma | 100 |
|
|
VKC: Vernal keratoconjunctivitis.
|